Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study

Liao, Xuejiao1; Li, Dapeng1; Liu, Jie2; Liu, Zhi3; Ma, Zhenghua1; Dong, Jingke1; Yang, Xiangyi1; Shu, Dan1; Yuan, Jing1; Liu, Lei1,4; Zhang, Zheng1,4,5

2022-12-15

10.1186/s12985-022-01944-6

VIROLOGY JOURNAL   影响因子和分区

1743-422X

BackgroundClinical data on patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant are limited, especially on clinical status after the application of antibody therapy. MethodsWe evaluated clinical status in patients with the SARS-CoV-2 delta variant after BRII-196 and BRII-198 treatment in an infectious disease hospital in China. We collected data on clinical symptoms, laboratory tests, radiological characteristics, viral load, anti-SARS-CoV-2 antibodies, treatment, and outcome. ResultsIn mid-June 2021, 36 patients with delta variant infection were identified in Shenzhen. The most common symptoms at illness onset were cough (30.6%), fever (22.2%), myalgia (16.7%), and fatigue (16.7%). A small number of patients in this study had underlying diseases, including diabetes (5.6%) and hypertension (8.3%). The application of BRII-196 and BRII-198 can rapidly increase anti-SARS-CoV-2 IgG. The median peak IgG levels in the antibody treatment group were 32 times higher than those in the control group (P < 0.001). The time from admission to peak IgG levels in the antibody treatment group (mean: 10.2 days) was significantly shorter than that in the control group (mean: 17.7 days). Chest CT score dropped rapidly after antibody therapy, with a mean duration of 5.74 days from admission to peak levels. ConclusionThe results of this study suggest that the application of BRII-196 and BRII-198 antibody therapy improved clinical status in patients with SARS-CoV-2 delta variant infection.

COVID-19 SARS-CoV-2 Antibody therapy Delta variant Clinical manifestation

SCI

英语

第一 ; 通讯

Science and Technology Innovation Committee of Shenzhen Municipality[82025022] ; Emergency Key Program of Guangzhou Laboratory["JSGG20200207155251653","JSGG20220226090002003"] ; Central Charity Fund of Chinese Academy of Medical Science[EKPG21-29] ; [2020-PT310-009]

Virology

Virology

WOS:000899601000002

BMC

Web of Science

1.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Affiliated Hosp 2, Sch Med,Inst Hepatol,Natl Clin Res Ctr Infect Dis, Shenzhen 518112, Guangdong, Peoples R China
2.Tianjin Med Univ Gen Hosp, Dept Neurol, Tianjin 300052, Peoples R China
3.Southern Univ Sci & Technol, Shenzhen Peoples Hosp 3, Affiliated Hosp 2, Sch Med,Dept Pulm Dis 3, Shenzhen 518112, Guangdong, Peoples R China
4.Chinese Acad Med Sci, Shenzhen Res Ctr Communicable Dis Diag & Treatment, Shenzhen 518112, Guangdong, Peoples R China
5.Guangdong Key Lab Antiinfect Drug Qual Evaluat, Shenzhen 518112, Guangdong, Peoples R China

Liao, Xuejiao,Li, Dapeng,Liu, Jie,et al. Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study[J]. VIROLOGY JOURNAL,2022,19(1).

Liao, Xuejiao.,Li, Dapeng.,Liu, Jie.,Liu, Zhi.,Ma, Zhenghua.,...&Zhang, Zheng.(2022).Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study.VIROLOGY JOURNAL,19(1).

Liao, Xuejiao,et al."Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study".VIROLOGY JOURNAL 19.1(2022).